ABSCIENCES (EPA:AB) | WebDisclosure

Basculer en Français

8295	Companies
114863	Keywords
55304	Articles
62446	Press releases

Home
Companies
ABSCIENCES

PRESS RELEASE

published on 10/10/2024 at 08:27, 1 month 11 days ago

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
AB Science presents financial results for the first half of 2024, updates on clinical development in ALS and MS, positive results in Covid-19 study, and intellectual property strengthening. AB announces capital increase and coverage initiations. Press Release by AB Science SA

Financial Results Capital Increase Clinical Development Intellectual Property AB Science
BRIEF

published on 09/30/2024 at 08:34, 1 month 21 days ago

AB Science announces a capital increase of 5.0 million euros

Capital Increase Clinical Development AB Science Masitinib European Investors
BRIEF

published on 09/30/2024 at 08:34, 1 month 21 days ago

AB Science annonce une augmentation de capital de 5,0 millions d’euros

Augmentation De Capital Développement Clinique AB Science Masitinib Investisseurs Européens
PRESS RELEASE

published on 09/30/2024 at 08:29, 1 month 21 days ago

AB Science annonce une augmentation de capital de 5,0 millions d’euros
AB Science annonce avec succès une augmentation de capital de 5 millions d’euros par placement privé pour financer le développement clinique de AB8939

Placement Privé Augmentation De Capital Développement Clinique AB Science AB8939
BRIEF

published on 09/23/2024 at 17:56, 1 month 27 days ago

AB Science fait le point sur le développement du masitinib dans les formes progressives de sclérose en plaques

Sclérose En Plaques Traitement Masitinib ECTRIMS 2024 Neurodégénératif
BRIEF

published on 09/23/2024 at 17:56, 1 month 27 days ago

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis

Multiple Sclerosis Treatment Masitinib ECTRIMS 2024 Neurodegenerative
PRESS RELEASE

published on 09/23/2024 at 17:51, 1 month 27 days ago

AB Science fait aujourd'hui le point sur le développement du masitinib dans les formes progressives de la sclérose en plaques suite à la conférence ECTRIMS 2024
AB Science fait le point sur le développement du masitinib dans les formes progressives de la sclérose en plaques après la conférence ECTRIMS 2024

Sclérose En Plaques AB Science Masitinib ECTRIMS 2024 Étude MAXIMS
PRESS RELEASE

published on 09/23/2024 at 17:51, 1 month 27 days ago

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024, showing promising results in phase 2B/3 study AB07002

Phase 3 Study AB Science Masitinib ECTRIMS 2024 Progressive Multiple Sclerosis
BRIEF

published on 07/08/2024 at 08:01, 4 months 13 days ago

AB Science annonce les résultats positifs de l'étude de phase 2 sur le masitinib dans le traitement du COVID-19

Essai Clinique Étude De Phase 2 COVID 19 AB Science Masitinib
BRIEF

published on 07/08/2024 at 08:01, 4 months 13 days ago

AB Science Announces Positive Results of Phase 2 Study for Masitinib in COVID-19

COVID-19 Clinical Trial Phase 2 Study AB Science Masitinib

Accesswire

Published on 11/21/2024 at 12:00, 1 hour 5 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 1 hour 5 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 35 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 3 hours 2 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 3 hours 5 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 30 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 50 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 58 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 5 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 35 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 7 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 7 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 7 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 58 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 45 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE